Bicycle Therapeutics reports positive ESMO 2024 data: 45% ORR for zelenectide pevedotin in mUC

BICYCLE THERAPEUTICS PLC

Zelenectide pevedotin monotherapy in mUC: 45% ORR (38 evaluable patients), 11.1 months median duration of response.
BT5528 in mUC: 45% ORR in 6.5 mg/m² Q2W expansion cohort; EphA2 expression correlates with response.
Low treatment-related peripheral neuropathy: 28% with zelenectide, 19% with BT5528; no Grade ≥3 events.
BT7480 in advanced solid tumors: favorable safety, 13 of 39 patients stable disease, 2 unconfirmed PRs in cervical cancer.
Global Phase 2/3 Duravelo-2 registrational trial for zelenectide pevedotin in mUC is enrolling.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.